Mr. Pierre Laurin is a senior executive with over 30 years of experience in the pharmaceutical and biotechnology industry.
Involved in the development of Prometic’s platform technology since 1989, Mr. Laurin founded Prometic Life Sciences Inc. in 1994. He served as Chairman until March 7, 2011 and serves as President and Chief Executive Officer of the Corporation since its inception.
Among other achievements, he took the Corporation public on the Toronto Stock Exchange and has since raised over $650 million through equity and debt financing and multinational funding. Mr. Laurin’s corporate development achievements also include the successful close of multiple licensing agreements and partnership agreements with multinationals, including two strategic agreements with the American Red Cross.
Mr. Laurin’s prior experience also includes positions with various pharmaceutical companies, including Nordic Laboratories (now Sanofi) where he played a pivotal role in the commercial success of Cardizem® in Canada.
Mr. Laurin holds a B.Sc. in Pharmacy and a Master’s degree in Pharmaceutical Sciences from the University of Montreal.
Bruce is the Chief Operating Officer of Prometic Life Sciences (PLI), a global biopharmaceutical company. As COO, Bruce oversees the company’s commercial, strategy, marketing, manufacturing, supply chain and business development functions.
An accountant by training, he has spent over two decades working in the life sciences and pharmaceutical industry. He has more than twelve years’ experience with PLI and has held a number of senior global positions across the organisation.
Prior to being appointed COO in 2014, Bruce was the Group CFO, a role he had held since 2008. Bruce brings a proven track record of success in strategic acquisitions and in raising debt and equity finance. As the finance director for Ardana, a speciality pharmaceutical company, he was responsible for raising the venture capital for the company’s successful (?) IPO.
As well as being a chartered accountant, Bruce also brought to the role many years of experience in general management and operations. Prior to joining Prometic, Bruce worked as a senior director for CV Therapeutics, a NASDAQ listed biopharmaceutical company, with a market capitalisation of over US$1 Billion.
Bruce is a graduate of Heriot-Watt University where he gained a BA in Accountancy and Computer Science. He is a member of the Institute of Chartered Accountants of Scotland and a Fellow of the Institute of Directors. He is also a Non-Executive Director and Chair of the Audit Committee of Imanova Limited.
Bruce splits his time between the group’s HQ in Montreal, Canada and its UK office in Cambridge.
Mr. Patrick Sartore joined Prometic in 2006 as Senior Legal Counsel – Intellectual Property, was nominated Corporate Secretary of the Corporation in 2007. Mr. Sartore held the position of General Counsel and Corporate Secretary from May 2013 to May 2015, at which date he was appointed Chief Legal Officer and Corporate Secretary.
Mr. Sartore was previously employed by Univalor Inc. as Legal Counsel and Leger Robic Richard, L.L.P., a firm specializing in Intellectual Property, Corporate and Commercial Law, as an associate attorney. Mr. Sartore has extensive experience in the areas of intellectual property, technology transfer, licensing and commercialization, private and public financing as well as general corporate and commercial law, namely in the biopharmaceutical field.
Mr. Sartore graduated from the University of Montreal with a Bachelor of Law (LLB) in 1999 and was called to the Bar of Québec in 2001. Mr. Sartore also holds a Bachelor of Science, with Distinction, from Concordia University.
Dr. John Moran MD, FRACP, FACP, has served as Chief Medical Officer of Prometic since March 1, 2014. From 2010 until joining the Corporation, Dr. Moran was Vice President, Clinical Affairs – Home modalities at DaVita Healthcare Partners Inc. where he had the overall responsibility for quality of care and related business issues for over 20,000 home dialysis patients in over 1,000 care centers.
Previously, Dr. Moran served for eight years as Senior Vice President, Clinical Affairs for Satellite Healthcare. Dr. Moran also served for, five years at Baxter Healthcare, as Global Medical Director for the Renal Division and for two years as Vice President for Clinical Development and Marketing.
Mr. Bruce Wendel was Chief Strategy Officer of Hepalink USA since June 2012. Mr. Wendel was Acting Chief Executive Officer of Scientific Protein Laboratories LLC from December 2014 to June 2015, a subsidiary of Shenzhen Hepalink Pharmaceutical CO., Ltd. From 2011 to 2012, he was consultant in the pharmaceutical industry.
Mr. Wendel served as Vice Chairman and Chief Executive Officer of Abraxis BioScience until October 15, 2010, when Abraxis was acquired by Celgene Corporation. He was with Abraxis BioScience as of May 2006 and served as Executive Vice President of Corporate Development of Abraxis BioScience until being appointed as Executive Vice President of Corporate Operations and Development in November 2007.
Mr. Wendel joined American Pharmaceutical Partners (APP) in 2004 as Vice President of Corporate Development. He began his 14 years with Bristol-Myers Squibb as in-house counsel before shifting to business and corporate development. Before joining APP, he served as Vice President, Business Development and Licensing for IVAX Corporation, a generic drug manufacturer.
Previously, Mr. Wendel served in the legal departments of Playtex and Combe. He earned a Juris Doctorate degree from Georgetown University Law School, where he was an editor of Law and Policy in International Business, and a B.S. from Cornell University.